Fingerpaint Names New Global President
The global commercialization partner for the biopharma industry appointed Bill McEllen as Global President. McEllen first joined Fingerpaint in 2016 and has been a biopharma commercialization leader for 30 years on both the client and agency side. Now he will be responsible for overseeing the company’s integrated business units, including 1798, Leaderboard Branding, Engage, MedThink, and Fingerpaint Marketing, as well as its more than 700 worldwide employees. With this move, Fingerpaint Founder Ed Mitzen will serve as Chairman and CEO as he continues to focus on growing the company’s capabilities through acquisitions.
“Bill’s experience and extensive understanding of the global challenges faced by the evolving biopharma landscape make him a natural fit to lead the company while staying true to the foundation Fingerpaint was built on,” Mitzen said in a statement. “Our people and our clients will continue to benefit from his forward-thinking approach.”
Medicx Health Promotes a New SVP
Medicx Health, a major provider of commercialization of data and analytics software and services that enable pharmaceutical and healthcare brands to better profile and communicate with target audiences, promoted Virginia Evans to Senior Vice President of Account Management and Analytics. Having joined the company in 2019, Evans has been instrumental in delivering strong campaign performance to clients. She will now be responsible for meeting client needs for both media and commercial analytics. Evans will continue to lead account management’s support of Medicx’s Micro-Neighborhood Targeting products as well as lead a new Consulting team that develops and delivers Medicx Health’s advanced analytics offerings.
Eric Trepanier, PharmD, CFA, Executive Vice President & General Manager commented about Evans’ promotion: “We are excited to promote her to SVP of Account Management and Analytics where she will bring her wealth of experience and client focus to deliver this same value to our clients with our SaaS and custom analytics products. Virginia is also a great example of our culture, living every day as a humble, hungry, and people-smart team player.”
The company focused on personal electrocardiogram (ECG) technology, is strengthening its executive team with the addition of Jessica Weinstein as Senior Vice President of Marketing. She will help AliveCor to achieve its goal of becoming a premier provider of remote cardiological care for providers, payers, employers, and patients. Weinstein brings with her 20 years of experience in driving marketing initiatives to impact consumers’ lives and deliver meaningful business results.
Envision Pharma Group
Julie Beeso joined the global technology-enabled scientific communications company as its Global Director, Professional Development and Engagement. Beeso’s 25 years of experience will help her develop, communicate, and execute a comprehensive professional development and talent management strategy for Envision Scientific Solutions. She will also be responsible for ESS engagement and relations, talent placement and retention, and overseeing performance management.
The leading digital life sciences marketing agency named industry veteran Anna Kotis as its new President. She will help the company continue to build year-over-year growth and acumen in the agency landscape by focusing on scientific communications, brand strategy, and data and analytics. Kotis has over 20 years of experience driving business growth and leading product launches at major players such as Pfizer and Forest Laboratories.
M Booth Health
Stacey Bernstein was named CEO of the health communications agency as it closes its most successful year of growth to date. Bernstein will replace former CEO Tim Bird who is transitioning to Chairman. She is respected for counseling clients on the convergence of digital and health communications, pushing boundaries to develop uniquely creative programs focused on positively impacting patient outcomes.
Marc Levesque, PhD, MD joined the pharma giant as its new Vice President, Immunology Discovery and site head of the Merck Exploratory Science Center in Cambridge. He left his position as Senior Director of Immunology at AbbVie to join Merck. Dr. Levesque supports cross-functional scientific coordination between different therapeutic areas and scientific teams to identify new therapies for patients with autoimmune and inflammatory disorders.
Healthcare marketing giant Ogilvy Health has named Adam Hessel its new Chief Creative Officer to oversee all creative output for the agency in North America. Hessel joins the company from his role as CCO at Harrison & Star and with a track record of inspiring work and bold, innovative ideas.
Omnicom Health Group
The powerhouse health marketing agency promoted Gena M. Pemberton to Chief Diversity, Equity, and Inclusion Officer. She is charged with helping the network as it is committed to creating an inclusive, supportive work environment where all employees are valued, accepted, and have equal access to rewarding career opportunities and growth. In her 18 months at the company, Pemberton launched the large, unique, cross-company program, Healthy Inclusion, which includes a DEI University.
A global leader in AI-based diagnostic software in pathology, Paige promoted two leadership members; Andy Moye, PhD, as CEO and Jill Stefanelli, PhD, as President and Chief Business Officer. Dr. Moye was previously Chief Commercial Officer, where he led clinical sales and commercial strategy, including the U.S. launch of Paige Prostate, the first and only AI-based pathology product to receive FDA approval for use in detecting cancer in prostate biopsies. He will now lead the entire company and executive team in its next phase of commercial growth. Dr. Stefanelli previously served as Chief Precision Medicine Officer, leading the company’s strategic partnerships with life sciences companies and biomarker development strategy.
A biopharmaceutical company developing disease-modifying genetic medicines using its proprietary LNP delivery platform, appointed Shehnaaz Suliman, MD, MBA, MPhil to CEO and member of the Board of Directors. Dr. Suliman has over 25 years of experience building and transforming small and large biopharmaceutical companies. She will guide the company as it grows its pipeline, which includes programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.
Telecure Technologies Inc.
Eli Dusenbury, Telecure’s Chief Financial Officer, has been appointed to the company’s Board of Directors. The health IT company develops tech to make healthcare more accessible and efficient and Dusenbury has been key to its success. His experience in financial reporting and acquisitions makes him a trusted and invaluable asset to the Board.